<!DOCTYPE html><html lang="en" ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta name="theme-color" media="(prefers-color-scheme: light)" content="#f7f7f7"><meta name="theme-color" media="(prefers-color-scheme: dark)" content="#1b1b1e"><meta name="apple-mobile-web-app-capable" content="yes"><meta name="apple-mobile-web-app-status-bar-style" content="black-translucent"><meta name="viewport" content="width=device-width, user-scalable=no initial-scale=1, shrink-to-fit=no, viewport-fit=cover" ><meta name="generator" content="Jekyll v4.3.2" /><meta property="og:title" content="Quantitative Iodine-Based Material Decomposition Images with Spectral CT Imaging for Differentiating Prostatic Carcinoma from Benign Prostatic Hyperplasia" /><meta property="og:locale" content="en" /><meta name="description" content="Rationale and Objectives" /><meta property="og:description" content="Rationale and Objectives" /><link rel="canonical" href="https://clinicaltree.github.io/posts/quantitative-iodine-based-material-decomposition-images-with-spectral-ct-imaging-for-differentiating/" /><meta property="og:url" content="https://clinicaltree.github.io/posts/quantitative-iodine-based-material-decomposition-images-with-spectral-ct-imaging-for-differentiating/" /><meta property="og:site_name" content="Radiology Tree" /><meta property="og:type" content="article" /><meta property="article:published_time" content="2013-07-31T17:00:00+00:00" /><meta name="twitter:card" content="summary" /><meta property="twitter:title" content="Quantitative Iodine-Based Material Decomposition Images with Spectral CT Imaging for Differentiating Prostatic Carcinoma from Benign Prostatic Hyperplasia" /><meta name="twitter:site" content="@twitter_username" /><meta name="google-site-verification" content="RFHVRgQqK0eGjftEMCTDhsDrR8cJ_ZYcfCX52gXW8KM" /> <script type="application/ld+json"> {"@context":"https://schema.org","@type":"BlogPosting","dateModified":"2023-04-10T02:43:55+00:00","datePublished":"2013-07-31T17:00:00+00:00","description":"Rationale and Objectives","headline":"Quantitative Iodine-Based Material Decomposition Images with Spectral CT Imaging for Differentiating Prostatic Carcinoma from Benign Prostatic Hyperplasia","mainEntityOfPage":{"@type":"WebPage","@id":"https://clinicaltree.github.io/posts/quantitative-iodine-based-material-decomposition-images-with-spectral-ct-imaging-for-differentiating/"},"url":"https://clinicaltree.github.io/posts/quantitative-iodine-based-material-decomposition-images-with-spectral-ct-imaging-for-differentiating/"}</script><title>Quantitative Iodine-Based Material Decomposition Images with Spectral CT Imaging for Differentiating Prostatic Carcinoma from Benign Prostatic Hyperplasia | Radiology Tree</title><link rel="apple-touch-icon" sizes="180x180" href="/assets/img/favicons/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="/assets/img/favicons/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="/assets/img/favicons/favicon-16x16.png"><link rel="manifest" href="/assets/img/favicons/site.webmanifest"><link rel="shortcut icon" href="/assets/img/favicons/favicon.ico"><meta name="apple-mobile-web-app-title" content="Radiology Tree"><meta name="application-name" content="Radiology Tree"><meta name="msapplication-TileColor" content="#da532c"><meta name="msapplication-config" content="/assets/img/favicons/browserconfig.xml"><meta name="theme-color" content="#ffffff"><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://fonts.gstatic.com" crossorigin><link rel="dns-prefetch" href="https://fonts.gstatic.com" crossorigin><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://cdn.jsdelivr.net" ><link rel="dns-prefetch" href="https://cdn.jsdelivr.net" ><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Lato&family=Source+Sans+Pro:wght@400;600;700;900&display=swap"><link rel="preconnect" href="https://www.google-analytics.com" crossorigin="use-credentials"><link rel="dns-prefetch" href="https://www.google-analytics.com"><link rel="preconnect" href="https://www.googletagmanager.com" crossorigin="anonymous"><link rel="dns-prefetch" href="https://www.googletagmanager.com"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@6.2.1/css/all.min.css"><link rel="stylesheet" href="/assets/css/style.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/magnific-popup@1.1.0/dist/magnific-popup.min.css"> <script src="https://cdn.jsdelivr.net/npm/jquery@3.6.1/dist/jquery.min.js"></script> <script type="text/javascript"> class ModeToggle { static get MODE_KEY() { return "mode"; } static get MODE_ATTR() { return "data-mode"; } static get DARK_MODE() { return "dark"; } static get LIGHT_MODE() { return "light"; } static get ID() { return "mode-toggle"; } constructor() { if (this.hasMode) { if (this.isDarkMode) { if (!this.isSysDarkPrefer) { this.setDark(); } } else { if (this.isSysDarkPrefer) { this.setLight(); } } } let self = this; /* always follow the system prefers */ this.sysDarkPrefers.addEventListener('change', () => { if (self.hasMode) { if (self.isDarkMode) { if (!self.isSysDarkPrefer) { self.setDark(); } } else { if (self.isSysDarkPrefer) { self.setLight(); } } self.clearMode(); } self.notify(); }); } /* constructor() */ get sysDarkPrefers() { return window.matchMedia("(prefers-color-scheme: dark)"); } get isSysDarkPrefer() { return this.sysDarkPrefers.matches; } get isDarkMode() { return this.mode === ModeToggle.DARK_MODE; } get isLightMode() { return this.mode === ModeToggle.LIGHT_MODE; } get hasMode() { return this.mode != null; } get mode() { return sessionStorage.getItem(ModeToggle.MODE_KEY); } /* get the current mode on screen */ get modeStatus() { if (this.isDarkMode || (!this.hasMode && this.isSysDarkPrefer)) { return ModeToggle.DARK_MODE; } else { return ModeToggle.LIGHT_MODE; } } setDark() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.DARK_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.DARK_MODE); } setLight() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.LIGHT_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.LIGHT_MODE); } clearMode() { $('html').removeAttr(ModeToggle.MODE_ATTR); sessionStorage.removeItem(ModeToggle.MODE_KEY); } /* Notify another plugins that the theme mode has changed */ notify() { window.postMessage({ direction: ModeToggle.ID, message: this.modeStatus }, "*"); } flipMode() { if (this.hasMode) { if (this.isSysDarkPrefer) { if (this.isLightMode) { this.clearMode(); } else { this.setLight(); } } else { if (this.isDarkMode) { this.clearMode(); } else { this.setDark(); } } } else { if (this.isSysDarkPrefer) { this.setLight(); } else { this.setDark(); } } this.notify(); } /* flipMode() */ } /* ModeToggle */ const modeToggle = new ModeToggle(); </script><body data-topbar-visible="true"><div id="sidebar" class="d-flex flex-column align-items-end"><div class="profile-wrapper text-center"><div id="avatar"> <a href="/" class="mx-auto"> <img src="https://storage.googleapis.com/clinicalpub.com/images/favicon.png" alt="avatar" onerror="this.style.display='none'"> </a></div><div class="site-title"> <a href="/">Radiology Tree</a></div><div class="site-subtitle font-italic">Update every day the best and the lastest articles, books, journals, clinical cases, videos, images... for radiologist</div></div><ul class="w-100"><li class="nav-item"> <a href="/" class="nav-link"> <i class="fa-fw fas fa-home ml-xl-3 mr-xl-3 unloaded"></i> <span>HOME</span> </a><li class="nav-item"> <a href="/categories/" class="nav-link"> <i class="fa-fw fas fa-stream ml-xl-3 mr-xl-3 unloaded"></i> <span>CATEGORIES</span> </a><li class="nav-item"> <a href="/tags/" class="nav-link"> <i class="fa-fw fas fa-tag ml-xl-3 mr-xl-3 unloaded"></i> <span>TAGS</span> </a><li class="nav-item"> <a href="/archives/" class="nav-link"> <i class="fa-fw fas fa-archive ml-xl-3 mr-xl-3 unloaded"></i> <span>ARCHIVES</span> </a><li class="nav-item"> <a href="/about/" class="nav-link"> <i class="fa-fw fas fa-info-circle ml-xl-3 mr-xl-3 unloaded"></i> <span>ABOUT</span> </a></ul><div class="sidebar-bottom mt-auto d-flex flex-wrap justify-content-center align-items-center"> <button class="mode-toggle btn" aria-label="Switch Mode"> <i class="fas fa-adjust"></i> </button> <span class="icon-border"></span> <a href="https://github.com/clinicaltree" aria-label="github" target="_blank" rel="noopener noreferrer"> <i class="fab fa-github"></i> </a> <a href="https://twitter.com/twitter_username" aria-label="twitter" target="_blank" rel="noopener noreferrer"> <i class="fab fa-twitter"></i> </a> <a href="javascript:location.href = 'mailto:' + ['clinicalpub.team','gmail.com'].join('@')" aria-label="email" > <i class="fas fa-envelope"></i> </a> <a href="/feed.xml" aria-label="rss" > <i class="fas fa-rss"></i> </a></div></div><div id="topbar-wrapper"><div id="topbar" class="container d-flex align-items-center justify-content-between h-100 pl-3 pr-3 pl-md-4 pr-md-4"> <span id="breadcrumb"> <span> <a href="/"> Home </a> </span> <span>Quantitative Iodine-Based Material Decomposition Images with Spectral CT Imaging for Differentiating Prostatic Carcinoma from Benign Prostatic Hyperplasia</span> </span> <i id="sidebar-trigger" class="fas fa-bars fa-fw"></i><div id="topbar-title"> Post</div><i id="search-trigger" class="fas fa-search fa-fw"></i> <span id="search-wrapper" class="align-items-center"> <i class="fas fa-search fa-fw"></i> <input class="form-control" id="search-input" type="search" aria-label="search" autocomplete="off" placeholder="Search..."> </span> <span id="search-cancel" >Cancel</span></div></div><div id="main-wrapper" class="d-flex justify-content-center"><div id="main" class="container pl-xl-4 pr-xl-4"><div class="row"><div id="core-wrapper" class="col-12 col-lg-11 col-xl-9 pr-xl-4"><div class="post pl-1 pr-1 pl-md-2 pr-md-2"><h1 data-toc-skip>Quantitative Iodine-Based Material Decomposition Images with Spectral CT Imaging for Differentiating Prostatic Carcinoma from Benign Prostatic Hyperplasia</h1><div class="post-meta text-muted"> <span> Posted <em class="" data-ts="1375290000" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Jul 31, 2013 </em> </span> <span> Updated <em class="" data-ts="1681094635" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Apr 10, 2023 </em> </span><div class="d-flex justify-content-between"> <span> By <em> <a href="">Xiao-Fei Zhang MD</a> </em>, <em> <a href="">Qing Lu MD</a> </em>, <em> <a href="">Lian-Ming Wu MD</a> </em>, <em> <a href="">Ai Hua Zou MD</a> </em>, <em> <a href="">Xiao Lan Hua MD</a> </em>, <em> <a href="">Jian Rong Xu MD</a> </em> </span><div> <span class="readtime" data-toggle="tooltip" data-placement="bottom" title="1941 words"> <em>10 min</em> read</span></div></div></div><div class="post-content"><h2 id="rationale-and-objectives"><span class="mr-2">Rationale and Objectives</span><a href="#rationale-and-objectives" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>To investigate the value of iodine-based material decomposition images produced via spectral computed tomography (CT) in differentiating prostate cancer (PCa) from benign prostate hyperplasia (BPH).</p><h2 id="materials-and-methods"><span class="mr-2">Materials and Methods</span><a href="#materials-and-methods" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Fifty-six male patients underwent CT examination with spectral imaging during arterial phase (AP), venous phase (VP), and parenchymal phase (PP) of enhancement. Iodine concentrations of lesions were measured and normalized to that of the obturator internus muscle. Lesion CT values at 75 keV (corresponding to the energy of polychromatic images at 120 kVp) were measured and also normalized; their differences between AP and VP, VP and PP, and PP and AP were also obtained. The two-sample <em>t</em> -test was performed for comparisons. A receiver operating characteristic curve was generated to establish the threshold for normalized iodine concentration (NIC).</p><h2 id="results"><span class="mr-2">Results</span><a href="#results" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Fifty-two peripheral lesions were found, which were confirmed by biopsy as 28 cases of PCa and 24 BPHs. The NICs of prostate cancers significantly differed from those of the BPHs: 2.38 ± 1.72 compared with 1.21 ± 0.72 in AP, respectively, and 2.67 ± 0.61 compared with 2.27 ± 0.77 in VP. Receiver operating characteristic analysis indicated that an NIC of 1.24 in the AP provided a sensitivity of 88% and a specificity of 71% for differentiating PCa from BPH.</p><h2 id="conclusions"><span class="mr-2">Conclusions</span><a href="#conclusions" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Spectral CT imaging enabled quantitative depiction of contrast medium uptake in prostatic lesions and improved sensitivity and specificity for differentiating PCa from BPH.</p><p>Cancer of the prostate (PCa) is the most common cancer in men and the second most common cause of cancer death . PCa and benign prostate hyperplasia (BPH) both rank among the 10 most diagnosed diseases in men over the age of 65 years . Although there is considerable overlap between BPH and PCa in symptom and risk profiles, management approaches are very different and appropriate differential diagnostic evaluation is crucial to achieve the best possible outcomes.</p><p>The main diagnostic tools for suspected carcinoma of the prostate are digital rectal examination, prostate-specific antigen (PSA) levels and associated parameters, and color Doppler transrectal sonographically guided biopsy . Although the latter is currently the best technique for detecting cancer in patients with elevated PSA or a positive digital rectal examination, it has its limitations. For example, septic complications after prophylactic antibiotics occur in 1% to 4% of patients and may require aggressive therapy . Therefore, a reliable noninvasive method of distinguishing malignant from benign disease would be of considerable benefit.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="materials-and-methods-1"><span class="mr-2">Materials and methods</span><a href="#materials-and-methods-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="patients"><span class="mr-2">Patients</span><a href="#patients" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="ct-examinations"><span class="mr-2">CT Examinations</span><a href="#ct-examinations" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="image-generation"><span class="mr-2">Image Generation</span><a href="#image-generation" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="ct-analysis"><span class="mr-2">CT Analysis</span><a href="#ct-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="cecd-targeted-biopsy-and-pathological-analysis"><span class="mr-2">CECD-Targeted Biopsy and Pathological Analysis</span><a href="#cecd-targeted-biopsy-and-pathological-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/QuantitativeIodineBasedMaterialDecompositionImageswithSpectralCTImagingforDifferentiatingProstaticCarcinomafromBenignProstaticHyperplasia/0_1s20S1076633213002079.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/QuantitativeIodineBasedMaterialDecompositionImageswithSpectralCTImagingforDifferentiatingProstaticCarcinomafromBenignProstaticHyperplasia/0_1s20S1076633213002079.jpg" alt="Figure 1, Prostate gland of 64-year-old man with elevated prostate-specific antigen (PSA) 7.2 ng/mL. (a,b) Two consecutive monochromatic computed tomography (CT) images that enable the best visualization of suspicious lesions obtained at 75-keV energy. (c) Postcontrast ultrasonogram, (d) precontrast ultrasonogram, and (e) ultrasonogram showing blood flow. The suspicious lesion was found in the left peripheral zone ( arrow ), with the same-size lesion shown on both ultrasonogram and monochromatic CT images." class="lazyload" data-proofer-ignore></a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/QuantitativeIodineBasedMaterialDecompositionImageswithSpectralCTImagingforDifferentiatingProstaticCarcinomafromBenignProstaticHyperplasia/1_1s20S1076633213002079.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/QuantitativeIodineBasedMaterialDecompositionImageswithSpectralCTImagingforDifferentiatingProstaticCarcinomafromBenignProstaticHyperplasia/1_1s20S1076633213002079.jpg" alt="Figure 2, Prostate gland of 73-year-old man with elevated prostate-specific antigen (PSA) 9.3 ng/mL. (a,b) Two consecutive image levels that enable the best vision of suspicious lesions of monochromatic computed tomography images obtained at 75-keV energy level. (c) Postcontrast ultrasonogram. (d) Precontrast ultrasonogram. The suspicious lesion was found in the left peripheral zone ( arrow )." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="quantitative-analysis"><span class="mr-2">Quantitative Analysis</span><a href="#quantitative-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="statistical-analyses"><span class="mr-2">Statistical Analyses</span><a href="#statistical-analyses" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="results-1"><span class="mr-2">Results</span><a href="#results-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="ct-and-cecd-targeted-biopsy"><span class="mr-2">CT and CECD-Targeted Biopsy</span><a href="#ct-and-cecd-targeted-biopsy" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="image-analysis"><span class="mr-2">Image Analysis</span><a href="#image-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/QuantitativeIodineBasedMaterialDecompositionImageswithSpectralCTImagingforDifferentiatingProstaticCarcinomafromBenignProstaticHyperplasia/2_1s20S1076633213002079.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/QuantitativeIodineBasedMaterialDecompositionImageswithSpectralCTImagingforDifferentiatingProstaticCarcinomafromBenignProstaticHyperplasia/2_1s20S1076633213002079.jpg" alt="Figure 3, A 67-year-old man with abnormal findings on digital rectal examination with prostate-specific antigen (PSA) 13 ng/mL, diagnosed adenocarcinoma of the prostate with Gleason score of 9 at transrectal sonographically guided biopsy for the computed tomography (CT)-suspicious lesion. (a–c) Transverse monochromatic CT images obtained at 75-keV energy level, and (d–f) iodine-based material decomposition images. (a,d) Single spectral CT acquisition during arterial phase, (b,e) venous phase, and (d,f) parenchymal phase. Monochromatic images and iodine concentration image in early phase show lesion of obviously abnormal hyperdensity in the left, the basal part of the prostatic peripheral zone infiltrating the seminal vesicle." class="lazyload" data-proofer-ignore></a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/QuantitativeIodineBasedMaterialDecompositionImageswithSpectralCTImagingforDifferentiatingProstaticCarcinomafromBenignProstaticHyperplasia/3_1s20S1076633213002079.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/QuantitativeIodineBasedMaterialDecompositionImageswithSpectralCTImagingforDifferentiatingProstaticCarcinomafromBenignProstaticHyperplasia/3_1s20S1076633213002079.jpg" alt="Figure 4, A 77-year-old man with abnormal findings on digital rectal examination with prostate-specific antigen (PSA) 9.2 ng/mL, diagnosed benign prostate hyperplasia at transrectal sonographically guided biopsy for all cores including the computed tomography (CT)-suspicious lesion. (a–c) Transverse monochromatic CT images obtained at 75-keV energy level, and (d–f) iodine-based material decomposition images from single spectral CT acquisition during (a,d) arterial phase, (b,e) venous phase, and (d,f) parenchymal phase (section thickness, 3.75 mm). Monochromatic and iodine concentration images in early phase show lesion of abnormal focal hyperdensity in the right prostatic peripheral zone. There are also lesions in the central gland ( black arrow )." class="lazyload" data-proofer-ignore></a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/QuantitativeIodineBasedMaterialDecompositionImageswithSpectralCTImagingforDifferentiatingProstaticCarcinomafromBenignProstaticHyperplasia/4_1s20S1076633213002079.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/QuantitativeIodineBasedMaterialDecompositionImageswithSpectralCTImagingforDifferentiatingProstaticCarcinomafromBenignProstaticHyperplasia/4_1s20S1076633213002079.jpg" alt="Figure 5, An 82-year-old man with abnormal findings on digital rectal examination with prostate-specific antigen (PSA) 15 ng/mL, diagnosed adenocarcinoma of prostate with Gleason score of 7 at transrectal sonographically guided biopsy for the computed tomography (CT)-suspicious lesion. (a–c) Transverse monochromatic CT images obtained at 75 keV, and (d–f) iodine-based material decomposition images from single spectral CT acquisition during (a,d) arterial phase, (b,e) venous phase, and (d,f) parenchymal phase (section thickness, 3.75 mm). Monochromatic and iodine concentration images in early phase show lesion of abnormal focal hyperdensity in the left prostatic peripheral zone." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="quantitative-analysis-1"><span class="mr-2">Quantitative Analysis</span><a href="#quantitative-analysis-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 1</p><p>Quantitative Assessment of Iodine Concentrations and Computed Tomography (CT) Number Differences in Different Scanning Phases between Prostate Cancer (PCa) and Benign Prostate Hyperplasia (BPH)</p><p>PCa ( <em>n</em> = 28) BPH ( <em>n</em> = 24)<em>P</em> Value ∗ NIC AP † 2.38 ± 1.72 (1.55, 2.09) 1.21 ± 0.72 (0.90, 1.52) .00 (.41, 1.93) NIC VP † 2.67 ± 0.61 (2.35, 2.88) 2.27 ± 0.77 (1.95, 2.60) .04 (0, .78) NIC PP 2.51 ± 0.49 (2.28, 2.70) 2.35 ± 0.82 (2.00, 2.69) .37 (−.20, .53) NCT AP 0.96 ± 0.16 (0.90, 1.04) 0.90 ± 0.30 (0.78, 1.03) .33 (−.07, .19) NCT VP 1.30 ± 0.16 (1.22, 1.36) 1.28 ± 0.40 (1.14, 1.42) .79 (−.12, .16) NCT PP 1.23 ± 0.17 (1.14, 1.29) 1.22 ± 0.33 (1.11, 1.32) .83 (−.11, .13) DNCT VA ‡ 0.34 ± 0.15 (0.26, 0.39) 0.38 ± 0.28 (0.26, 0.50) .47 (−.17, .08) DNCT PV ‡ −0.07 ± 0.13 (−0.13, −0.18) −0.06 ± 0.15 (−0.13, 0) .87 (−.09, .07) DNCT PA ‡ 0.27 ± 0.19 (0.20, 0.34) 0.32 ± 0.31 (0.19, 0.45) .47 (−.19, .09)</p><p>AP, arterial phase; VP, venous phase; PP, parenchymal phase.</p><p>Value are mean ± SD (95% confidence interval).</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/QuantitativeIodineBasedMaterialDecompositionImageswithSpectralCTImagingforDifferentiatingProstaticCarcinomafromBenignProstaticHyperplasia/5_1s20S1076633213002079.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/QuantitativeIodineBasedMaterialDecompositionImageswithSpectralCTImagingforDifferentiatingProstaticCarcinomafromBenignProstaticHyperplasia/5_1s20S1076633213002079.jpg" alt="Figure 6, Box plots of normalized iodine concentration (NIC) for prostate cancer (PCa) and benign prostate hyperplasia (BPH) in arterial phase (AP) and venous phase (VP). The lower quartile, medium, upper quartile, and middle half NIC summaries of PCa were higher than those of BPHs in AP and VP." class="lazyload" data-proofer-ignore></a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/QuantitativeIodineBasedMaterialDecompositionImageswithSpectralCTImagingforDifferentiatingProstaticCarcinomafromBenignProstaticHyperplasia/6_1s20S1076633213002079.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/QuantitativeIodineBasedMaterialDecompositionImageswithSpectralCTImagingforDifferentiatingProstaticCarcinomafromBenignProstaticHyperplasia/6_1s20S1076633213002079.jpg" alt="Figure 7, Quantitative measurements for prostate cancer (PCa) and benign prostate hyperplasia (BPH) during the arterial phase (AP), venous phase (VP), and parenchymal phase (PP). The normalized iodine concentration (NIC) curve for PCa shows a greater early enhancement and faster washout than that of BPHs. On the other hand, there was little difference between PCas and BPHs during the three phases in the degree of enhancement, as quantified in value changes. Each point represents the mean value." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="diagnostic-implications"><span class="mr-2">Diagnostic Implications</span><a href="#diagnostic-implications" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/QuantitativeIodineBasedMaterialDecompositionImageswithSpectralCTImagingforDifferentiatingProstaticCarcinomafromBenignProstaticHyperplasia/7_1s20S1076633213002079.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/QuantitativeIodineBasedMaterialDecompositionImageswithSpectralCTImagingforDifferentiatingProstaticCarcinomafromBenignProstaticHyperplasia/7_1s20S1076633213002079.jpg" alt="Figure 8, Receiver operating characteristic analyses using quantification of normalized iodine concentration (NIC) resulted in moderately significant discriminatory power between patients with prostate cancer and BPH. The value 1.24 as the normalized iodine density threshold was established by calculating the maximal Youden index. With this value, the sensitivity (SEN) and specificity (SPE) were 89% and 71%, respectively. NICAP, NIC of arterial phase; NICVP, NIC of the venous phase; NICPP, NIC of the parenchymal phase." class="lazyload" data-proofer-ignore></a></p><p>Table 2</p><p>ormalized Iodine Concentration (NIC) Thresholds, Sensitivities, and Specificities for Distinguishing Prostate Cancer from Benign Prostate Hyperplasia</p><p>Phase AUC ∗ <em>P</em> † Threshold Sensitivity (%) ‡ Specificity (%) ‡ <em>P</em> § NIC AP 0.87 ± 0.05 (0.73, 0.94) .0054 (.06, .35) 1.24 88, 28, (72, 91) 71, 24, (65, 89) .03 NIC VP 0.66 ± 0.08 (0.49, 0.80) 1.96 84, 28, (69, 90) 55, 24, (49, 77) NIC PP 0.63 ± 0.08 (0.47, 0.77) 2.00 87, 28, (74, 90) 42, 24, (41, 68)</p><p>AP, arterial phase. VP, venous phase; PP, parenchymal phase.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="discussion"><span class="mr-2">Discussion</span><a href="#discussion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>P=−ln(II0)=d1μ1(E)+d2μ2(E) P</p><p>=</p><p>−</p><p>ln</p><p>(</p><p>I</p><p>I</p><p>0</p><p>)</p><p>=</p><p>d</p><p>1</p><p>μ</p><p>1</p><p>(</p><p>E</p><p>)</p><p>+</p><p>d</p><p>2</p><p>μ</p><p>2</p><p>(</p><p>E</p><p>)</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>P′=Pμ1(E)=d1+d2μ2(E)μ1(E) P</p><p>′</p><p>=</p><p>P</p><p>μ</p><p>1</p><p>(</p><p>E</p><p>)</p><p>=</p><p>d</p><p>1</p><p>+</p><p>d</p><p>2</p><p>μ</p><p>2</p><p>(</p><p>E</p><p>)</p><p>μ</p><p>1</p><p>(</p><p>E</p><p>)</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="references"><span class="mr-2">References</span><a href="#references" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><ul><li><p>1. Ferlay J., Parkin D.M., Steliarova-Foucher E.: Estimates of the cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010 Mar; 4: pp. 765-781.</p><li><p>2. Issa M.M., Regan T.S.: Medical therapy for benign prostatic hyperplasia: present and future impact. Am J Manag Care 2007; 13: pp. S4-S9.</p><li><p>3. Arcangeli C.G., Ornstein D.K., Keetch D.W., et. al.: Prostate-specific antigen as a screening test for prostate cancer: the United States experience. Urol Clin North Am 1997; 24: pp. 299-306.</p><li><p>4. Catalona W.J., Beiser J.A., Smith D.S.: Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies. J Urol 1997; 158: pp. 2162-2167.</p><li><p>5. Letran J.L., Blase A.B., Loberiza F.R., et. al.: Repeat ultrasound guided prostate needle biopsy: use of free-to-total prostate specimen antigen ratio in predicting prostatic carcinoma. J Urol 1998; 160: pp. 426-429.</p><li><p>6. Kelly I.M., Lees W.R., Rickards D., et. al.: Prostate cancer and the role of color Doppler US. Radiology 1993; 189: pp. 153-156.</p><li><p>7. Rifkin M.D., Sudakoff G.S., Alexander A.A.: Prostate: techniques, results, and potential applications of color Doppler US scanning. Radiology 1993; 186: pp. 509-513.</p><li><p>8. Bree R.L.: The role of color Doppler and staging biopsies in prostate cancer detection. Urology 1997; 49: pp. 31-34.</p><li><p>9. Lavoipierre A.M., Snow R.M., Frydenberg M., et. al.: Prostatic cancer: role of color Doppler imaging in transrectal sonography. AJR Am J Roentgenol 1998; 171: pp. 205-210.</p><li><p>10. Puig J., Darnell A., Bermudez P., et. al.: Transrectal ultra sound-guided prostate biopsy: is antibiotic prophylaxis necessary?. Eur Radiol 2006; 16: pp. 939-943.</p><li><p>11. Sheikh M., Hussein A.Y., Kehinde E.O., et. al.: Patients’ tolerance and early complications of transrectal sonographically guided prostate biopsy: prospective study of 300 patients. J Clin Ultrasound 2005; 33: pp. 452-456.</p><li><p>12. Brown G., Macvicar D.A., Ayton V., et. al.: The role of intravenous contrast enhancement in magnetic resonance imaging of prostatic carcinoma. Clin Radiol 1995; 50: pp. 601-606.</p><li><p>13. Cruz M., Tsuda K., Narumi Y., et. al.: Characterization of low-intensity lesions in the peripheral zone of prostate on pre-biopsy endorectal coil MR imaging. Eur Radiol 2002; 12: pp. 357-365.</p><li><p>14. Price J.M., Davidson A.J.: Computed tomography in the evaluation of the suspected carcinomatous prostate. Urol Radiol 1979; 1: pp. 39-42.</p><li><p>15. Prando A., Wallace Sidney: Helical CT of prostate cancer: early clinical experience. AJR Am J Roentgenol 2000; 175: pp. 343-346.</p><li><p>16. Lin X.Z., Miao F., Li J.Y., et. al.: High-definition CT gemstone spectral imaging of the brain: initial results of selecting optimal monochromatic image for beam-hardening artifacts and image noise reduction. J Comput Assist Tomogr 2011; 35: pp. 294-297.</p><li><p>17. Zhao L.Q., He W., Li J.Y., et. al.: Improving image quality in portal venography with spectral CT imaging. Eur J Radiol 2012; 81: pp. 1677-1681.</p><li><p>18. Lv P.J., Lin X.Z., Li J.Y., et. al.: Differentiation of small hepatic hemangioma from small hepatocellular carcinoma: recently introduced spectral CT method. Radiology 2011; 259: pp. 720-729.</p><li><p>19. Geyer L.L., Scherr M., Körner M., et. al.: Imaging of acute pulmonary embolism using a dual energy CT system with rapid kVp switching: initial results. Eur J Radiol 2011; (March) [Epub ahead of print]</p><li><p>20. Mitterberger M., Aigner F., Pinggera G.M., et. al.: Contrast-enhanced colour Doppler-targeted prostate biopsy: correlation of a subjective blood-flow rating scale with the histopathological outcome of the biopsy. BJU Int 2010; 106: pp. 1315-1318.</p><li><p>21. Padhani A.R., Hayes C., Landau S., et. al.: Reproducibility of quantitative dynamic MRI of normal human tissues. NMR Biomed 2002; 15: pp. 143-153.</p><li><p>22. Dorfman D.D., Alf E.: Maximum likelihood estimation of parameters of signal detection theory—a direct solution. Psychometrika 1968; 33: pp. 117-124.</p><li><p>23. Obuchowski N.A.: ROC analysis. AJR Am J Roentgenol 2005; 184: pp. 364-372.</p><li><p>24. Bigler S.A., Deering R.E., Brawer M.K.: Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol 1993; 24: pp. 220-226.</p><li><p>25. Hawighorst H., Knapstein P.G., Knopp M.V., et. al.: Cervical carcinoma: standard and pharmacokinetic analysis of time intensity curve for assessment of tumors angiogenesis and patient survival. MAGMA 1999; 8: pp. 55-62.</p><li><p>26. Checkley D., Tessier J.J., Kendrew J., et. al.: Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signaling inhibitor, in PC-3 prostate tumors. Br J Cancer 2003; 89: pp. 1889-1895.</p><li><p>27. Wiedenbeck M.: Total x-ray attenuation coefficients from 40KeV to 412KeV. Phys Rev 1962; 126: pp. 1009-1010. (1962)</p><li><p>28. Ferlay J., Autier P., Boniol M., et. al.: Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: pp. 581-592.</p><li><p>29. Halpern E.J., Ramey J.R., Strup S.E.: Detection of prostate carcinoma with contrast-enhanced sonography using intermittent harmonic imaging. Cancer 2005; 104: pp. 2373-2383.</p><li><p>30. Corcetti L., Lencioni R., DeB eni S.: Targeting liver lesions for radiofrequency ablation. An experimental feasibility study using a CT-US fusion imaging system. Invest Radiol 2008; 43: pp. 33-39.</p></ul></div><div class="post-tail-wrapper text-muted"><div class="post-meta mb-3"> <i class="far fa-folder-open fa-fw mr-1"></i> <a href='/categories/academic-radiology/'>Academic Radiology</a>, <a href='/categories/volume-20/'>Volume 20</a>, <a href='/categories/issue-8/'>Issue 8</a></div><div class="post-tags"> <i class="fa fa-tags fa-fw mr-1"></i> <a href="/tags/journals/" class="post-tag no-text-decoration" >Journals</a> <a href="/tags/general-radiology/" class="post-tag no-text-decoration" >General Radiology</a></div><div class="post-tail-bottom d-flex justify-content-between align-items-center mt-3 pt-5 pb-2"><div class="license-wrapper"> This post is licensed under <a href="https://creativecommons.org/licenses/by/4.0/"> CC BY 4.0 </a> by the author.</div><div class="share-wrapper"> <span class="share-label text-muted mr-1">Share</span> <span class="share-icons"> <a href="https://twitter.com/intent/tweet?text=Quantitative%20Iodine-Based%20Material%20Decomposition%20Images%20with%20Spectral%20CT%20Imaging%20for%20Differentiating%20Prostatic%20Carcinoma%20from%20Benign%20Prostatic%20Hyperplasia%20-%20Radiology%20Tree&url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fquantitative-iodine-based-material-decomposition-images-with-spectral-ct-imaging-for-differentiating%2F" data-toggle="tooltip" data-placement="top" title="Twitter" target="_blank" rel="noopener" aria-label="Twitter"> <i class="fa-fw fab fa-twitter"></i> </a> <a href="https://www.facebook.com/sharer/sharer.php?title=Quantitative%20Iodine-Based%20Material%20Decomposition%20Images%20with%20Spectral%20CT%20Imaging%20for%20Differentiating%20Prostatic%20Carcinoma%20from%20Benign%20Prostatic%20Hyperplasia%20-%20Radiology%20Tree&u=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fquantitative-iodine-based-material-decomposition-images-with-spectral-ct-imaging-for-differentiating%2F" data-toggle="tooltip" data-placement="top" title="Facebook" target="_blank" rel="noopener" aria-label="Facebook"> <i class="fa-fw fab fa-facebook-square"></i> </a> <a href="https://t.me/share/url?url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fquantitative-iodine-based-material-decomposition-images-with-spectral-ct-imaging-for-differentiating%2F&text=Quantitative%20Iodine-Based%20Material%20Decomposition%20Images%20with%20Spectral%20CT%20Imaging%20for%20Differentiating%20Prostatic%20Carcinoma%20from%20Benign%20Prostatic%20Hyperplasia%20-%20Radiology%20Tree" data-toggle="tooltip" data-placement="top" title="Telegram" target="_blank" rel="noopener" aria-label="Telegram"> <i class="fa-fw fab fa-telegram"></i> </a> <i id="copy-link" class="fa-fw fas fa-link small" data-toggle="tooltip" data-placement="top" title="Copy link" data-title-succeed="Link copied successfully!"> </i> </span></div></div></div></div></div><div id="panel-wrapper" class="col-xl-3 pl-2 text-muted"><div class="access"><div id="access-lastmod" class="post"><div class="panel-heading">Recently Updated</div><ul class="post-content pl-0 pb-1 ml-1 mt-2"><li><a href="/posts/neurometabolites-alteration-in-the-acute-phase-of-mild-traumatic-brain-injury-mtbi/">Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI)</a><li><a href="/posts/reinforcing-the-importance-and-feasibility-of-implementing-a-low-dose-protocol-for-ct-guided-biopsie/">Reinforcing the Importance and Feasibility of Implementing a Low-dose Protocol for CT-guided Biopsies</a><li><a href="/posts/rethinking-the-pgy-1-basic-clinical-year/">Rethinking the PGY-1 Basic Clinical Year</a><li><a href="/posts/single-injection-dual-phase-cone-beam-ct-dp-cbct-vascular-anatomy-assessment-and-occult-nodule-det/">Single Injection Dual-Phase Cone Beam CT (DP-CBCT) Vascular Anatomy Assessment and Occult Nodule Detection; Have We Reached the Focus?</a><li><a href="/posts/the-yellow-scale-is-superior-to-the-gray-scale-for-detecting-acute-ischemic-stroke-on-a-monitor-disp/">The Yellow Scale Is Superior to the Gray Scale for Detecting Acute Ischemic Stroke on a Monitor Display in Computed Tomography</a></ul></div><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="toc-wrapper" class="pl-0 pr-4 mb-5"><div class="panel-heading pl-3 pt-2 mb-2">Contents</div><nav id="toc"></nav></div><script src="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.js"></script></div></div><div class="row"><div id="tail-wrapper" class="col-12 col-lg-11 col-xl-9 pl-3 pr-3 pr-xl-4 mt-5"><div id="related-posts" class="mb-2 mb-sm-4"><h3 class="pt-2 mb-4 ml-1" data-toc-skip>Further Reading</h3><div class="card-deck mb-4"><div class="card"> <a href="/posts/arthritis-in-black-and-white-3rd-ed/"><div class="card-body"> <em class="small" data-ts="1375290000" data-df="ll" > Jul 31, 2013 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Arthritis in Black and White, 3rd Ed.</h3><div class="text-muted small"><p> Long-awaited third edition of the Arthritis in Black and White has finally arrived. The second edition was published in 1997 and remains a classic “must-read” textbook for radiologists-in-training....</p></div></div></a></div><div class="card"> <a href="/posts/automated-patient-identity-recognition-by-analysis-of-chest-radiograph-features/"><div class="card-body"> <em class="small" data-ts="1375290000" data-df="ll" > Jul 31, 2013 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Automated Patient Identity Recognition by Analysis of Chest Radiograph Features</h3><div class="text-muted small"><p> Rationale and Objectives The aim of this study was to develop a computerized scheme for automated identity recognition based on chest radiograph features. Materials and Methods The proposed meth...</p></div></div></a></div><div class="card"> <a href="/posts/automated-subtraction-ct-angiography-for-visualization-of-the-whole-brain-vasculature/"><div class="card-body"> <em class="small" data-ts="1375290000" data-df="ll" > Jul 31, 2013 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Automated Subtraction CT Angiography for Visualization of the Whole Brain Vasculature</h3><div class="text-muted small"><p> Rationale and Objectives To develop an automated computed tomography angiography (CTA) imaging protocol that allows visualization of the whole brain vasculature and evaluate the clinical usefulnes...</p></div></div></a></div></div></div><div class="post-navigation d-flex justify-content-between"> <a href="/posts/quantitative-analysis-of-coronary-plaque-composition-by-dual-source-ct-in-patients-with-acute-non-st/" class="btn btn-outline-primary" prompt="Older"><p>Quantitative Analysis of Coronary Plaque Composition by Dual-Source CT in Patients with Acute Non–ST-Elevation Myocardial Infarction Compared to Patients with Stable Coronary Artery Disease Correlated with Virtual Histology Intravascular Ultrasound</p></a> <a href="/posts/the-world-of-computers/" class="btn btn-outline-primary" prompt="Newer"><p>The World of Computers</p></a></div></div></div></div><div id="search-result-wrapper" class="d-flex justify-content-center unloaded"><div class="col-12 col-sm-11 post-content"><div id="search-hints"><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="search-results" class="d-flex flex-wrap justify-content-center text-muted mt-3"></div></div></div></div><footer><div class="container pl-lg-4 pr-lg-4"><div class="d-flex justify-content-between align-items-center text-muted ml-md-3 mr-md-3"><div class="footer-left"><p class="mb-0"> © 2023 <a href="https://twitter.com/username">Clinical Team</a>. <span data-toggle="tooltip" data-placement="top" title="Except where otherwise noted, the blog posts on this site are licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) License by the author.">Some rights reserved.</span></p></div><div class="footer-right"><p class="mb-0">Using the <a href="https://jekyllrb.com" target="_blank" rel="noopener">Jekyll</a> theme <a href="https://github.com/cotes2020/jekyll-theme-chirpy" target="_blank" rel="noopener">Chirpy</a>.</p></div></div></div></footer><div id="mask"></div><a id="back-to-top" href="#" aria-label="back-to-top" class="btn btn-lg btn-box-shadow" role="button"> <i class="fas fa-angle-up"></i> </a><div id="notification" class="toast" role="alert" aria-live="assertive" aria-atomic="true" data-animation="true" data-autohide="false"><div class="toast-header"> <button type="button" class="ml-2 ml-auto close" data-dismiss="toast" aria-label="Close"> <span aria-hidden="true">&times;</span> </button></div><div class="toast-body text-center pt-0"><p class="pl-2 pr-2 mb-3">A new version of content is available.</p><button type="button" class="btn btn-primary" aria-label="Update"> Update </button></div></div><script src="https://cdn.jsdelivr.net/npm/simple-jekyll-search@1.10.0/dest/simple-jekyll-search.min.js"></script> <script> SimpleJekyllSearch({ searchInput: document.getElementById('search-input'), resultsContainer: document.getElementById('search-results'), json: '/assets/js/data/search.json', searchResultTemplate: '<div class="pl-1 pr-1 pl-sm-2 pr-sm-2 pl-lg-4 pr-lg-4 pl-xl-0 pr-xl-0"> <a href="{url}">{title}</a><div class="post-meta d-flex flex-column flex-sm-row text-muted mt-1 mb-1"> {categories} {tags}</div><p>{snippet}</p></div>', noResultsText: '<p class="mt-5">Oops! No results found.</p>', templateMiddleware: function(prop, value, template) { if (prop === 'categories') { if (value === '') { return `${value}`; } else { return `<div class="mr-sm-4"><i class="far fa-folder fa-fw"></i>${value}</div>`; } } if (prop === 'tags') { if (value === '') { return `${value}`; } else { return `<div><i class="fa fa-tag fa-fw"></i>${value}</div>`; } } } }); </script> <script src="https://cdn.jsdelivr.net/combine/npm/magnific-popup@1.1.0/dist/jquery.magnific-popup.min.js,npm/lazysizes@5.3.2/lazysizes.min.js,npm/clipboard@2.0.11/dist/clipboard.min.js"></script> <script src="https://cdn.jsdelivr.net/combine/npm/dayjs@1.11.6/dayjs.min.js,npm/dayjs@1.11.6/locale/en.min.js,npm/dayjs@1.11.6/plugin/relativeTime.min.js,npm/dayjs@1.11.6/plugin/localizedFormat.min.js"></script> <script defer src="/assets/js/dist/post.min.js"></script> <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/js/bootstrap.bundle.min.js"></script> <script defer src="/app.js"></script> <script defer src="https://www.googletagmanager.com/gtag/js?id=G-L66SLQK23K"></script> <script> document.addEventListener("DOMContentLoaded", function(event) { window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-L66SLQK23K'); }); </script>
